Aerie Pharmaceuticals, Inc.
2030 Main Street, Suite 1500
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye. Aerie's first product, once-daily Rhopressa® (netarsudil ophthalmic solution) 0.02%, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was approved by the U.S. Food and Drug Administration (FDA) in December 2017. A link to the full product label is available on the Aerie website at http://investors.aeriepharma.com. Aerie’s second product candidate, once-daily RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed-dose combination of Rhopressa® and widely prescribed PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3 registration trials, Mercury 1 and Mercury 2, and also achieved successful 12-month safety and efficacy results in Mercury 1. The RoclatanTM NDA submission is expected to take place in the second quarter of 2018. Aerie is also focused on global expansion and the growth of its pipeline in ophthalmology. These development efforts include preclinical studies of AR-13503, a small molecule inhibitor of Rho kinase and protein kinase C that has demonstrated significant reduction in lesion size associated with wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in animal models, and AR-1105, a dexamethasone steroid with the potential to treat DME. Aerie is also exploring drug delivery opportunities using a bio-erodible polymer sourced from DSM that may provide sustained release of small molecules such as AR-13154 to the retina and through exclusive rights to PRINT® technology for ophthalmic indications, providing a manufacturing platform for precisely-sized implants.
Stock Symbol: AERI
Stock Exchange: NASDAQ
Our VISIONaerieS® have been working to develop a new class of glaucoma medication that targets the diseased trabecular meshwork, an unmet medical need.
187 articles with Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in New York, NY.
Conference Call and Webcast Today, November 6th, at 5:00 p.m. ET
Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Aerie Pharmaceuticals, Inc. announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018.
The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina, facility
Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe
European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa® in the United States
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
Aerie Pharmaceuticals, Inc. today announced the appointment of Damien Monaghan, Quality Director, reporting to Finbar O’Neill, EU Director, Quality & Regulatory Compliance.
Aerie Pharmaceuticals, Inc. today announced that Richard Rubino, Chief Financial Officer, will present at the Ophthalmology Futures European Forum.
8/27/2018Who made a splash in the biotech world this week? Here are some notable people.
Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
Dr. White previously held a related position at Alcon, a Novartis Company.
Clinical confirmation of the effect of Rhopressa® on trabecular meshwork outflow facility in patients with open-angle glaucoma or ocular hypertension
Conference Call and Webcast Today, August 8th, at 5:00 p.m. ET
Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the Canaccord Genuity Growth Conference on Thursday, August 9, 2018 at 1:30 p.m.
Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
Aerie Pharmaceuticals, Inc. announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018.
Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology
Promising Technology Platform to Potentially Deliver Therapies to Treat a Broad Spectrum of Ophthalmic Diseases.
Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019
Aerie Pharmaceuticals, Inc. reported that it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) earlier than scheduled, the FDA has completed its initial 60-day review of the NDA (new drug application) for Roclatan™
Aerie Pharmaceuticals Announces Deerfield’s Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield
Aerie Pharmaceuticals, Inc., today announced that the $125 million of senior secured convertible notes held by affiliates of Deerfield Management Company L.P. since September 2014 have been fully converted into 5,040,323 shares of Aerie common stock...
Aerie Pharmaceuticals, Inc. announced the appointment of Randall Brown as Director, Payer Marketing, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Brown will support the ongoing development and execution of strategies, programs and communication activities for the payer markets.
Mr. Coppola previously held related positions at Sanofi.
JMP Securities 2018 Life Science Conference on Thursday, June 21, 2018 at 2:00pm Eastern Time in New York, NY.